| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8a0748996704577980b7806fd22ade8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e378824e3997f0d55c33811189f4ad20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62551f55b4bdada5a39671e62ec0d7f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9985529ee812119b76fd420587d90ff4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1641 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-08 |
| filingDate |
2010-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_308409ffa1ee8359fb65d4b03131e3ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e166e70b42d25a5703159ea6e19f6b86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_650f7ac1acd0575928329404b162869f |
| publicationDate |
2012-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2012283332-A1 |
| titleOfInvention |
Transdermal delivery of metformin |
| abstract |
Provided is a transdermal metformin that is an effective alternative treatment modality in patients with insulin resistance. Transdermal metformin can be used in conditions where oral metformin is indicated such as Type 2 diabetes mellitus, pre-diabetes, polycystic ovarian syndrome, and other known diabetes associated disorders. One advantage of using transdermal metformin is its ability to bypass the gastrointestinal system. This allows the drug to not have the gastrointestinal side-effects associated with oral metformin. A surprising advantage of using transdermal metformin in accordance with this disclosure is a 90% decrease in dosage from the oral preparation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10925862-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11141409-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10952994-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019000815-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10765665-B2 |
| priorityDate |
2009-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |